Completed PHASE1 INTERVENTIONAL 1-arm NCT00412997

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Sponsor: Novartis

Conditions Cutaneous T-Cell Lymphoma Tumors

Interventions LBH589

Updated 5 times since 2017 Last updated: Nov 26, 2012 Started: Nov 30, 2006 Primary completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00412997, this PHASE1 trial focuses on Cutaneous T-Cell Lymphoma and Tumors and remains completed. Sponsored by Novartis, it has been updated 5 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan